{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:40:04Z","timestamp":1744252804173,"version":"3.40.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00914-2","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:35:31Z","timestamp":1744216531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the efficacy of sucroferric oxyhydroxide and lanthanum carbonate in the hyperphosphatemia of maintainable Hemodialysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Min","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YiJing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiQuan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"914_CR1","doi-asserted-by":"crossref","unstructured":"Marando M, Tamburello A, Salera D et al. Phosphorous metabolism and manipulation in chronic kidney disease. Nephrol (Carlton). 2024 Oct 21.","DOI":"10.1111\/nep.14407"},{"issue":"6","key":"914_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7326\/M17-2640","volume":"168","author":"M Ketteler","year":"2018","unstructured":"Ketteler M, Block GA, Evenepoel P. Et a1. Diagnosis, evaluation, prevention, and treatment of chronic kidney Disease-Mineral and bone disorder: Synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Ann Intern Med. 2018 Mar 20;168(6):422\u201330.","journal-title":"Ann Intern Med"},{"issue":"7","key":"914_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10157-021-02037-4","volume":"25","author":"J Li","year":"2021","unstructured":"Li J, He D, Zhao W, Wu X, et al. Association of mineral metabolism biomarkers with chronic kidney disease in Chinese adults. Clin Exp Nephrol. 2021;25(7):760\u201370.","journal-title":"Clin Exp Nephrol"},{"key":"914_CR4","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorde r (CKD-MBD). Kidney Int Suppl. 2017;7(1):1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"issue":"4","key":"914_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1159\/000505432","volume":"49","author":"G Lioulios","year":"2020","unstructured":"Lioulios G, Stangou M, Sarafidis PA. Chronic therapy with sucroferric oxyhydroxide does not affect iron and anemia markers in dialysis patients. Blood Purif. 2020;49(4):440\u20137.","journal-title":"Blood Purif"},{"issue":"5","key":"914_CR6","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00467-020-04805-y","volume":"36","author":"LA Greenbaum","year":"2021","unstructured":"Greenbaum LA, Jeck N, Klaus G, et al. Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2021;36(5):1233\u201344.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"914_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12882-019-1582-9","volume":"20","author":"K Kalantar-Zadeh","year":"2019","unstructured":"Kalantar-Zadeh K, Ficociello LH, Parameswaran V, et al. Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among Hemodialysis patients: A historical cohort study. BMC Nephrol. 2019;20(1):396.","journal-title":"BMC Nephrol"},{"issue":"3","key":"914_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.xkme.2020.01.009","volume":"2","author":"DW Coyne","year":"2020","unstructured":"Coyne DW, Ficociello LH, Parameswaran V, et al. Sucroferric oxyhydroxide in maintenance hemodialysis: A retrospective, Comparative cohort Study. Kidney Med. 2020;2(3):307\u201316.","journal-title":"Kidney Med"},{"issue":"5","key":"914_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00403-018-1832-x","volume":"310","author":"Z Kwan","year":"2018","unstructured":"Kwan Z, Bong YB, Tan LL, et al. Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res. 2018;310(5):443\u201351.","journal-title":"Arch Dermatol Res"},{"issue":"19","key":"914_CR10","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1001\/jama.2021.4807","volume":"325","author":"H Ogata","year":"2021","unstructured":"Ogata H, Fukagawa M, Hirakata H, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: The LANDMARK randomized clinical Trial. JAMA. 2021;325(19):1946\u201354.","journal-title":"JAMA"},{"key":"914_CR11","doi-asserted-by":"crossref","unstructured":"Cernaro V, Longhitano E, Calabrese V, et al. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure. Expert Opin Pharmacother. 2023 Sep-Dec;24(15):1737\u20131746.","DOI":"10.1080\/14656566.2023.2243817"},{"key":"914_CR12","doi-asserted-by":"crossref","unstructured":"Nakamura K, Nagata Y, Hiroyoshi T, et al. The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients. Clin Exp Nephrol. 2020 Apr;24(4):323\u2013329.","DOI":"10.1007\/s10157-019-01832-4"},{"issue":"1","key":"914_CR13","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1080\/0886022X.2021.1986068","volume":"43","author":"L Zhao","year":"2021","unstructured":"Zhao L, Liu A, Xu G. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: A meta-analysis. Ren Fail. 2021 Dec;43(1):1378\u201393.","journal-title":"Ren Fail"},{"issue":"1","key":"914_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000531869","volume":"148","author":"J Liu","year":"2024","unstructured":"Liu J, Zuo L, Walpen S, et al. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer carbonate in Chinese dialysis patients with hyperphosphataemia: A randomised, Open-Label, multicentre, 12-Week phase III Study. Nephron. 2024;148(1):22\u201333.","journal-title":"Nephron"},{"issue":"7","key":"914_CR15","first-page":"636","volume":"29","author":"X Deng","year":"2017","unstructured":"Deng X, Dai Q, Wan L, et al. Effects of multimodal combination dialysis on Klotho protein, FGF-23 and BNP in patients with maintenance hemodialysis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017 Jul;29(7):636\u20139. Chinese.","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"issue":"2","key":"914_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ckj\/sfy077","volume":"12","author":"F Koiwa","year":"2018","unstructured":"Koiwa F, Yokoyama K, Fukagawa M, et al. Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment. Clin Kidney J. 2018 Sep 19;12(2):294\u20139.","journal-title":"Clin Kidney J"},{"issue":"8","key":"914_CR17","first-page":"1330","volume":"32","author":"AC Covic","year":"2017","unstructured":"Covic AC, Floege J, Ketteler M, et al. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transpl. 2017 Aug 1;32(8):1330\u20138.","journal-title":"Nephrol Dial Transpl"},{"issue":"7","key":"914_CR18","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/ckj\/sfaa211","volume":"14","author":"MG Vervloet","year":"2021","unstructured":"Vervloet MG, Boletis IN, de Francisco ALM, et al. Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: A prospective observational study. Clin Kidney J. 2021;14(7):1770\u201379.","journal-title":"Clin Kidney J"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00914-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:05:21Z","timestamp":1744250721000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00914-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00914-2","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was approved by the Ethics Committee of China Rongtong Medical & Healthcare Group Tai\u2019an 88 Hospital. The study is in line with the World Medical Association Declaration of Helsinki. Before their admission to the study, a signed and dated informed consent was obtained from each patient. They were totally voluntary and could withdraw from the study at any time. We can get information that could identify individual participants during or after data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}